Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nippon Shinyaku CoTSE:4516 -0.80%80 Equity-to-Asset is 0.86 as of Jun. 2026, which is 2% above its 10-year median of 0.84. GuruFocus rates TSE:4516 with a GF Score™ of 80/100 and a GF Value™ of 円4,655.25 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Nippon Shinyaku Co ranks better than 89.28% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Nippon Shinyaku Co's Total Stockholders Equity for the quarter that ended in Jun. 2026 was 円295,412 Mil. Nippon Shinyaku Co's Total Assets for the quarter that ended in Jun. 2026 was 円345,153 Mil.
Therefore, Nippon Shinyaku Co's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.86.
The historical rank and industry rank for Nippon Shinyaku Co's Equity-to-Asset or its related term are showing as below:
TSE:4516'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.76 Med: 0.84 Max: 0.88
Current: 0.86
During the past 13 years, the highest Equity to Asset Ratio of Nippon Shinyaku Co was 0.88. The lowest was 0.76. And the median was 0.84.
TSE:4516's Equity-to-Asset is ranked better than 89.28% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs TSE:4516: 0.86
Nippon Shinyaku Co (TSE:4516) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Nippon Shinyaku Co Equity-to-Asset Related Terms
Nippon Shinyaku Co Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Nippon Shinyaku Co's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Nippon Shinyaku Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nippon Shinyaku Co Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nippon Shinyaku Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Nippon Shinyaku Co's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Nippon Shinyaku Co's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nippon Shinyaku Co (TSE:4516) has a Equity-to-Asset of 0.86 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Nippon Shinyaku Co and its competitors. This is near median its historical median of 0.84. Over the past decade, Nippon Shinyaku Co's Equity-to-Asset has ranged from 0.76 to 0.88. According to the industry distribution chart, Nippon Shinyaku Co ranks #108 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 10.7%.
Is Nippon Shinyaku Co's Equity-to-Asset too high?
Nippon Shinyaku Co's current Equity-to-Asset of 0.86 is near median its 10-year median of 0.84. Over the past 10 years, this metric has ranged from a low of 0.76 to a high of 0.88. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Nippon Shinyaku Co's value of 0.86 is 43.3% above this industry median. Based on the distribution chart, Nippon Shinyaku Co ranks #108 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Nippon Shinyaku Co has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nippon Shinyaku Co's Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Nippon Shinyaku Co ranks #108 out of 1007 companies for Equity-to-Asset. This places Nippon Shinyaku Co in the top 11% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.60. Nippon Shinyaku Co's value of 0.86 is 43.3% above this benchmark. Historically, Nippon Shinyaku Co's own Equity-to-Asset has ranged from 0.76 to 0.88 over the past decade. While the company's 10-year median is 0.84 vs. the industry median of 0.60, Nippon Shinyaku Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nippon Shinyaku Co's current Equity-to-Asset of 0.86 is 43.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Nippon Shinyaku Co and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nippon Shinyaku Co's current Equity-to-Asset is 0.86, which is near median its own 10-year median of 0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nippon Shinyaku Co stock overvalued right now?
Based on GuruFocus' analysis, Nippon Shinyaku Co (TSE:4516) is currently considered Modestly Undervalued. The stock's GF Value™ is 円4,655.25, compared to a current price of 円3,452.00 — trading 25.8% below its estimated fair value. The current Equity-to-Asset is 0.86, which is near median its 10-year median of 0.84 and 43.3% above the Drug Manufacturers industry median of 0.60. Nippon Shinyaku Co's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Nippon Shinyaku Co (TSE:4516), the current Equity-to-Asset is 0.86 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nippon Shinyaku Co (TSE:4516) Overvalued in 2026?
Based on GuruFocus' analysis, Nippon Shinyaku Co stock appears to be undervalued.
The current stock price of 円3,452.00 is trading 25.8% below its estimated GF Value™ of 円4,655.25.
GuruFocus considers Nippon Shinyaku Co to be Modestly Undervalued.
Key valuation signals for TSE:4516:
Equity-to-Asset: 0.86 (near median its 10-year median of 0.84)
GF Value™: 円4,655.25 vs. price of 円3,452.00 (25.8% below fair value)
Industry Position: 43.3% above the Drug Manufacturers median (#108 of 1007)
No single metric tells the full story. See the TSE:4516 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nippon Shinyaku Co Ltd is engaged in the pharmaceuticals and functional food businesses. The Pharmaceuticals Business develops and sells treatments for urological disorders, blood cancer, rare and intractable diseases, and gynecological conditions. The Functional Food Business produces and sells health food ingredients, quality-stabilizing preservatives, protein preparations, and supplements. It generates the majority of its revenue from the Pharmaceuticals segment.
80GF Score
Get the complete analysis for TSE:4516
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4516 has been successfully added to your 
